Home Cart Sign in  
Chemical Structure| 1639417-53-0 Chemical Structure| 1639417-53-0

Structure of Tenalisib
CAS No.: 1639417-53-0

Chemical Structure| 1639417-53-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tenalisib is a potent and selective dual PI3Kδ/γ inhibitor with IC50 of 24.5 nM and 33.2 nM for PI3Kδ and PI3Kγ, respectively. Its selectivity over α and β isoforms are more than 300-fold and 100-fold, respectively.

Synonyms: RP6530

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tenalisib

CAS No. :1639417-53-0
Formula : C23H18FN5O2
M.W : 415.42
SMILES Code : O=C1C(C2=CC=CC(F)=C2)=C([C@@H](NC3=C4N=CNC4=NC=N3)CC)OC5=C1C=CC=C5
Synonyms :
RP6530
MDL No. :MFCD28502205
InChI Key :HDXDQPRPFRKGKZ-INIZCTEOSA-N
Pubchem ID :86291103

Safety of Tenalisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tenalisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    PI3Kγ, IC50:33.2 nM

  • p110δ

    PI3Kδ, IC50:24.5 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03711604 Hematological Malignancies PHASE1|PHASE2 COMPLETED 2023-03-25 University of California, Hell... More >>en Diller Family Comprehensive Cancer Center, San Francisco, California, 94143, United States|Division of Hematology, University of Colorado,, Denver, Colorado, 80045, United States|Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, 44195, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Ltd. M.Zodelava Hematology Centre, Tbilisi, Georgia|Medivest - Institute of Hematology and Transfusiology, Tbilisi, Georgia|Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J., Chorzów, 41-503, Poland Less <<
NCT06189209 Triple Negative Breast Cancer ... More >>(TNBC) Less << PHASE2 RECRUITING 2025-03-25 HCG City Cancer Center, Vijaya... More >>wada, Andhra Pradesh, 520002, India|Narayana Hrudayala Majumdar Shaw Hospital, Bangalore, Karnataka, 560099, India|Tata Memorial Centre, Mumbai, Maharashtra, 400012, India|Mumbai Oncocare Centre, Mumbai, Maharashtra, 400056, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, 411004, India|Meenakshi Mission Hospital & Research Center, Madurai, Tamil Nadu, 625107, India|Nizams Institute of Medical Science, Hyderabad, Telangana, 500082, India Less <<
NCT02690727 Healthy PHASE1 COMPLETED 2025-03-16 Algorithme Pharma Inc, Quebec,... More >> H3P 3P1, Canada Less <<
NCT05239910 Peripheral T Cell Lymphoma PHASE2 WITHDRAWN 2025-05-27 The University of Texas MD And... More >>erson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT04204057 Leukemia, Lymphocytic, Chronic... More >>, B-Cell Less << PHASE2 COMPLETED 2020-10-02 University Multiprofile Hospit... More >>al for Active Treatment "Dr Georgi Stranski" Ltd.,, Pleven, 5800, Bulgaria|University Multiprofile Hospital for Active Treatment "Sv Ivan Rilski" Ltd, Sofia, 1431, Bulgaria|Ltd. M.Zodelava Hematology Centre, Tbilisi, Georgia|Medivest - Institute of Hematology and Transfusiology, Tbilisi, Georgia|Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J., Chorzow, 41-503, Poland|Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus, ?ód?, Poland Less <<
NCT02567656 Lymphoma, T-Cell, Peripheral|L... More >>ymphoma, T-Cell, Cutaneous Less << PHASE1 COMPLETED 2018-12-10 City of Hope, Duarte, Californ... More >>ia, 91010, United States|Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, 92868, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Emory University School of Medicine, Atlanta, Georgia, 30322, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-0944, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106-5028, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT02017613 Lymphoma, B-Cell|T-Cell Lympho... More >>ma Less << PHASE1 COMPLETED 2025-05-16 Rhizen Trial Site, Paris, Fran... More >>ce|Rhizen Trial Site 1, Milano, Italy|Rhizen Trial Site 2, Milano, Italy Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.04mL

2.41mL

1.20mL

24.07mL

4.81mL

2.41mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories